TORONTO, Feb. 10, 2020 (GLOBE NEWSWIRE) — MPX International Corporation (“MPX International,” “MPXI” or the “Company”) (CSE:MPXI;OTC:MPXOF) announced the opening of its inaugural Holyweed CBD retail flagship store in the heart of Geneva’s tourist district. The store is strategically located on one of Geneva’s busiest streets, Rue des Eaux-Vives, near the famed water fountain “Jet d’Eau,” Geneva’s largest tourist attraction.
The location carries all Holyweed ‘Swiss Certified Organic’ branded products as well as products from several other premium CBD brands curated by Holyweed. Holyweed products include: 100% Swiss grown cannabis light/high CBD dry flowers, pre-rolls, oil tinctures, Cannabricot – a Swiss-made apricot cannabis liquor and eau-de-vie, a cannabis tea. Holyweed is currently the only Swiss CBD brand that has been awarded the official ‘Swiss Certified Organic’ label, a distinction that aligns the Holyweed brand with Switzerland’s impeccable reputation for high quality consumer products.Photos of Holyweed accompanying this announcement are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/0c1c63e1-cf72-4dce-9cce-a9a057f46fe6https://www.globenewswire.com/NewsRoom/AttachmentNg/6cc3ede2-6fc2-4c7e-af6c-1d5590da53f7“This first Holyweed store in Geneva is another step in our European retail strategy to cement MPXI as trailblazers providing access to premium quality CBD products in Europe and beyond. Importantly, it also further underpins our assertion that Switzerland is our most immediate opportunity for revenue generation, second only to our already revenue generating Canadian operations,” said W. Scott Boyes, Chairman, President and CEO of MPXI. “The opening of this first retail location is on the heels of our very successful harvest of approximately 90,000 kilograms of Swiss-organic, high CBD biomass in the fall and continues to build on the strong momentum we are experiencing in this jurisdiction.”“Again, we are creating first mover advantages that positions MPXI for success as a global leader and will enable us to capture market share as the European CBD market continues to experience massive growth,” Mr. Boyes added. “Our growing traction in Switzerland strongly supports this.”This new retail location builds on the Company’s burgeoning European retail presence. In November 2019, MPXI opened its first retail “beleaf” branded CBD retail location in London’s Soho district.Enhancing the cultural zeitgeist, Holyweed has collaborated with famed photographer Henrik Purienne to create an exclusive art book called Wandering And Learning, distributed through exclusive concept stores and trend setting retail partners globally in order to further build Holyweed brand awareness, not only in Switzerland but globally.A photo of Wandering And Learning accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/d8c26f68-968f-43bf-9a4c-4912e68b3f0aIn January 2020, Holyweed sponsored a major cultural event in Switzerland with its official sponsorship of “Art Geneve,” one of Europe’s most successful contemporary art fairs.“Select forays such as these demonstrates Holyweed leading management expertise to build a global cannabis brand in order to further elevate and extend our brand recognition with discerning consumers,” said Daniel Fryer, Managing Director, Europe. “Those actions cement Holyweed’s position as the premium Swiss brand of organic certified CBD products within the immediate region and throughout Europe.”Later in 2020, MPXI expects to open a second Holyweed retail location in Zurich, which is Switzerland’s largest city.About Holyweed:18 Rue des Eaux-Vives
GenevaAbout MPX International Corporation
MPX International Corporation is focused on developing and operating assets across the global cannabis industry with an emphasis on cultivating, manufacturing and marketing products which include cannabinoids as their primary active ingredient.Cautionary Statement Regarding Forward-Looking InformationNOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS.For further information, please contact:MPX International Corporation
W. Scott Boyes, Chairman, President and CEO
Canada’s Legal Cannabis Industry Advocates for Equitable Financial Treatment
Toronto, Ontario–(Newsfile Corp. – March 27, 2020) – The regulated cannabis industry has recently united to address a critical issue it has faced since its inception: a lack of equitable access to banking services and financial support. The fallout from the COVID-19 pandemic has highlighted the need to fix this while demonstrating that cannabis is an essential product.
We commend the individuals and organizations that have been vocal in their support for the cause: Don Davies (MP), Nathaniel Erskine-Smith (MP), Scott Reid (MP), Dan Sutton (Tantalus Labs), The Canadian Chamber of Commerce, and the Cannabis Council of Canada. Their lobby efforts have been directed towards the Business Development Bank of Canada (BDC), Bill Morneau P.C., M.P. (Minister of Finance), and Navdeep Bains P.C., M.P. (Minister of Innovation, Science and Industry), in an attempt to influence federal decision makers.
In solidarity, Alan Aldous has created an educational website to highlight the positive contributions to the Canadian economy, www.LegalTender.ca. We have also organized a coalition of industry experts, associations, and companies to advocate for change, including the Cannabis Council of Canada, NORML Canada, the British Columbia Independent Cannabis Association, the Ontario Independent Cannabis Association, the Alberta Cannabis Micro Licence Association, and The Cannabis Conservatory.
“The cannabis industry is doing its best to provide Canadians with an uninterrupted supply of legal cannabis, but it is not immune to the effects of COVID-19. Cannabis businesses deserve access to the same financial support being made available to other industries. Cannabis sector jobs are just as worthy of protection as any other,” says Trina Fraser, a prominent cannabis industry lawyer at firm Brazeau Seller Law.
In just one day, hundreds of Canadians have signed this urgent petition (https://bit.ly/2QKvwTQ) advocating for equitable treatment by the Business Development Bank of Canada (BDC) and Federal Government of Canada. We are thrilled by the response so far, and encourage hard-working Canadians to sign, share, and have their voices heard.
About Alan Aldous
Alan Aldous is a public relations agency for the emerging cannabis and psychedelics markets led by leading Canadian cannabis media professionals. The agency works with all the major newswire distribution services across North America, which makes transitioning to Alan Aldous easy for companies with existing PR efforts.
For media contact Alex Krause, Head Publicist, 519-835-8345, firstname.lastname@example.org.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53883
REPEAT – AgraFlora Organics’ GTA Facility Receives Amendments Necessary to Launch CBD Business
VANCOUVER, British Columbia, March 27, 2020 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc. (“AgraFlora” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF) is pleased to announce its wholly owned subsidiary Sustainable Growth Strategic Capital Corp. (“SGSC”), a federally licensed cannabis company based in the Greater Toronto Area (GTA), has received Health Canada approval to commence extraction at its licensed facility pursuant to an amendment to its Standard Processing License. SGSC also holds Standard Cultivation and Medical Sales Licenses issued pursuant to the Cannabis Act.
SGSC has been actively engaged in the Canadian CBD business, working with partner farmers to optimize the harvest to hemp-crops to maximize the efficiency of subsequent CBD extraction. In March, SGSC commenced a trial extraction (the “Trial”) of hemp-biomass which will be extracted using third-party extraction services and sold as a combination of CBD Crude Oil, CBD Distillate and CBD Isolate to Canadian purchasers. If the Trial yields favourable results with respect to product quality, efficiency and margin SGSC intends to move quickly with a second production cycle of up to 1,300 KG of high-quality hemp biomass containing CBD concentrations over 8%.The current SGSC facility is designed to facility up to 250,000 kg of biomass extraction capacity utilizing chilled ethanol for primary extraction followed by distillation and/or isolation. SGSC intends to use the Trial and subsequent third party extraction cycles to properly design and size its in-house extraction capacity to maximize the profitability and return on capital invested. Once built, SGSC intends to improve its profitability by reducing the cost of extraction, purification and fulfilment by bringing those processes in-house. About AgraFlora Organics International Inc.AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Services Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company is also retrofitting a 51,500-square-foot good manufacturing practice (“GMP”) edibles manufacturing facility in Winnipeg, Manitoba. AgraFlora has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.ON BEHALF OF THE BOARD OF DIRECTORSBrandon Boddy
Chairman & CEO
T: (604) 398-3147 The CSE and Information Service Provider have not reviewed and does not accept responsibility for the accuracy or adequacy of this release.Forward-looking Information Cautionary StatementExcept for statements of historic fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company’s control. There are no assurances that the business plans for AgraFlora Organics described in this news release will come into effect on the terms or time frame described herein. The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company’s filings with Canadian securities regulators, which are available at www.sedar.com.
Israel Begins Cannabis Exports to Meet Unmet Medical Needs — CFN Media
Seattle, Washington–(Newsfile Corp. – March 27, 2020) – CFN Media (OTCQB: CNFN), the leading agency and financial media network dedicated to the legalized North American cannabis industry announces publication of an article discussing how Israel has shipped the first cannabis export to the UK, marking a new era in Israeli cannabis.
Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry.
In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market.
Click below to view more on Isracann Biosciences – Israel’s First Pure Play Cannabis Firm
Cannot view this video? Visit:
Unmet Need in Europe
BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”
The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.
This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.
Isracann Biosciences Poised to Move
Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade.
While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.
The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.
In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.).
CEO Video Interview #1
Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones
Cannot view this video? Visit:
Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones
Cannot view this video? Visit:
The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.
Click here to read the full article: https://bit.ly/2QNGwA1
About CFN Media
CFN Enterprises Inc. (OTCQB: CNFN) is the owner and operator of CFN Media, the leading agency and digital financial media network dedicated to the legal cannabis industry.
For Visitors and Viewers
CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.
For Cannabis Businesses & Companies
CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.
Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.
Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.
Learn how to become a CFN Media client company, brand or entrepreneur: https://www.cannabisfn.com/become-featured-company/
The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/53879
Cannabis2 weeks ago
Intec Pharma Reports Fourth Quarter and Year End 2019 Financial Results and Corporate Update
Cannabis4 weeks ago
Nutritional High Announces John Durfy as New Chief Executive Officer
Cannabis3 weeks ago
Cannabis Food and Beverage Market by Product Type, and Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2019–2026
Cannabis2 weeks ago
Allied Corp. Announces Corporate Update
Cannabis4 weeks ago
Agritek Holdings, Inc. Announces Focus on Production of CBG Enriched Hemp Material and Retail Products as New Research Uncovers Hidden Antibiotic Potential to Fight Viral Symptoms in Humans
Cannabis2 weeks ago
SparqOne Announces California Distribution of Iconic Cannabis Brands
Cannabis3 weeks ago
Hemp, Inc.’s Commentary Featured in Hemp Magazine Coverage on USDA Hemp Testing Rules
Cannabis3 weeks ago
Happy Brain Licenses Iconic Kushy Punch Brand